Compound ID | 1859
Class: Rifamycin
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Inhibits bacterial DNA-dependent RNA polymerase, thus inhibiting bacterial RNA synthesis |
| Propensity to select resistant mutants: | Yes |
| Description: | Semisynthetic, derived from rifampicin, nonabsorbable. Used for the treatment of gastrointestinal infections (approved for traveler's diarrhea caused only by noninvasive E. coli, overt hepatic encephalopathy recurrence, irritable bowel syndrome with diarrhea) |
| Institute where first reported: | Salix Pharmaceuticals |
| Year first mentioned: | 1980 |
| Highest development stage: | Approved by FDA in 2004 |
| Development status: | Approved, off-patent |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/6436173 |
| Guide to Pharmacology: | rifaximin |
| Citations: |
|